Fragment-based Drug Discovery Market Will be Worth US$ 1.15 Bn by 2023

A recent report on the global fragment based drug discovery market studied by Transparency Market Research (TMR) elaborates the factors that indicates the growth of the market in coming years. The market for fragmented based drugs discovery is expected to grow steadily during the forecast period of 2015 to 2023. The increasing popularity of newer techniques in fragment based drug discovery has grown significantly over the past few years. Its increasing scope in the biopharmaceuticals has also grown vastly that will further help the market to grow. Developing techniques has also improved by producing chemical series that contains lead like properties and has helped in creating improved conventional screening methods. The market also includes academic bodies, large companies, and CROs. The key contributors of the fragment based drug discovery market are Sygnature Discovery, Astex Pharmaceuticals, Beactica AB, Evotec A.G., and Charles River Laboratories International Inc

According to TMR, the market for fragment based drug discovery is expected to attain a CAGR of 14.4% during 2015 to 2023. The revenue during the same period is projected to raise up to US$1.15 bn by the end for forecast period of 2023. . The  fragment based drug discovery is segmented on the basis of end-user, service component, and geography. The end-user segment includes CROs, academic and research institutions, and biopharmaceuticals companies, among which the contribution of biopharmaceutical companies has grown significantly. Geographically, North America has its dominance for fragmented based drug market. The evaluation for North America is expected to grow up to 45.4% of the entire market during the forecast period.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

The Use of Lower Molecular Weight Has Grown the Demand for Fragment Based Drug Discovery Market

The market is experiencing high demand for fragment based drugs basically to overcome the difficulty faced in various complicated medical conditions. The market for fragment based drug discovery is expanding as it time saving and feasibility to access to fragment screening through biophysical techniques. The significant use of fragment based drug discovery has developed methods to use to design unique molecules, which uses lower molecular weight known as fragments or ligands. The effect of lead discovery has created a large number of fragment-derived compounds, which are significantly used in clinical trials and to treat patients through medicines.

Lesser Number of Fragment Libraries May Restrict the Fragment Based Drug Discovery Market to Grow Further In Future

The fragment based drug discovery market is comprised of five main components such as target enablement, fragment to lead optimization, fragment screening, fragment libraries, and model based on fragment binding. The market has also shown huge interest for covalent fragments, these are the fragments that is made through reaction which forma covalent bond with the protein. On the other hand, the market gets restricted when certain compounds have weak potency derived through fragment screening. Additionally, other restraints faced in the fragment based drug discovery market are lesser number of fragment libraries that will be immensely helpful for conducting further research. Despite certain restraints, fragment based methods has the ability to deliver new results in chemical biology (the use of chemical tools is done to understand and modulate biological systems and functions). Furthermore, the use of fragment based drug discovery is growing which also considers validation and target discovery.

Fragment-based Drug Discovery Market Opportunity will Rise to US$ 1.15 Bn by 2023

A recent report on the global fragment based drug discovery market studied by Transparency Market Research (TMR) elaborates the factors that indicates the growth of the market in coming years. The market for fragmented based drugs discovery is expected to grow steadily during the forecast period of 2015 to 2023. The increasing popularity of newer techniques in fragment based drug discovery has grown significantly over the past few years. Its increasing scope in the biopharmaceuticals has also grown vastly that will further help the market to grow. Developing techniques has also improved by producing chemical series that contains lead like properties and has helped in creating improved conventional screening methods. The market also includes academic bodies, large companies, and CROs. The key contributors of the fragment based drug discovery market are Sygnature Discovery, Astex Pharmaceuticals, Beactica AB, Evotec A.G., and Charles River Laboratories International Inc

According to TMR, the market for fragment based drug discovery is expected to attain a CAGR of 14.4% during 2015 to 2023. The revenue during the same period is projected to raise up to US$1.15 bn by the end for forecast period of 2023. . The fragment based drug discovery is segmented on the basis of end-user, service component, and geography. The end-user segment includes CROs, academic and research institutions, and biopharmaceuticals companies, among which the contribution of biopharmaceutical companies has grown significantly. Geographically, North America has its dominance for fragmented based drug market. The evaluation for North America is expected to grow up to 45.4% of the entire market during the forecast period.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

The Use of Lower Molecular Weight Has Grown the Demand for Fragment Based Drug Discovery Market

The market is experiencing high demand for fragment based drugs basically to overcome the difficulty faced in various complicated medical conditions. The market for fragment based drug discovery is expanding as it time saving and feasibility to access to fragment screening through biophysical techniques. The significant use of fragment based drug discovery has developed methods to use to design unique molecules, which uses lower molecular weight known as fragments or ligands. The effect of lead discovery has created a large number of fragment-derived compounds, which are significantly used in clinical trials and to treat patients through medicines.

Lesser Number of Fragment Libraries May Restrict the Fragment Based Drug Discovery Market to Grow Further In Future

The fragment based drug discovery market is comprised of five main components such as target enablement, fragment to lead optimization, fragment screening, fragment libraries, and model based on fragment binding. The market has also shown huge interest for covalent fragments, these are the fragments that is made through reaction which forma covalent bond with the protein. On the other hand, the market gets restricted when certain compounds have weak potency derived through fragment screening. Additionally, other restraints faced in the fragment based drug discovery market are lesser number of fragment libraries that will be immensely helpful for conducting further research. Despite certain restraints, fragment based methods has the ability to deliver new results in chemical biology (the use of chemical tools is done to understand and modulate biological systems and functions). Furthermore, the use of fragment based drug discovery is growing which also considers validation and target discovery.

Fragment-based Drug Discovery Market will Going to be Worth US$ 1.15 Bn by the End of 2023

Fragment-based Drug Discovery Market: Snapshot

The introduction of new techniques into the existing fragment-based drug discovery practices have created significant reductions in time and cost, driving the demand for such practices. Combinational chemistry and high-throughput screening are some of the more recently introduced practices that have helped make fragment-based drug discovery programs a lot faster and cheaper than before.

Additionally, as the usage of fragment-based drug discovery grows in the field of discovering weaker inhibitors, biophysical techniques become extremely useful. These techniques can be used to measure binding within fragment compounds that possess low affinity for binding.

Report Overview @ https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

The demand for fragment-based drug discovery, however, is expected to be greatly hindered by the lowered potency of fragment screening, the most popular component, in certain compounds. The drugs generated have a lower than required potency, thus deterring several end users from approaching this technique.

The collective impact of all such drivers and restraints can be seen on the global fragment-based drug discovery market, which is expected to expand at a CAGR of 14.4% from 2015 to 2023 by revenue. By the end of 2016, this revenue is expected to reach US$435.6 mn and US$1.15 bn by the end of 2023.

North America Expected to Continue Leading Demand for Fragment-based Drug Discovery Programs

By the end of 2023, the market value of fragment-based drug discovery techniques in North America is expected to be 45.4% of the global market. While this is a drop in market value from its 2014 statistic, North America will still enjoy being a leading geographical segment for advancements in fragment-based drug discovery techniques.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

The key factors responsible for the leading role of North America in fragment-based drug discovery programs is the high rate of research and development efforts undertaken by prominent market players in the region. The U.S. and Canada are both countries with advanced healthcare systems and infrastructures, and are often the base of advanced technological implementations, making North America the hub for the latest developments in fragment-based drug discovery.

This region is also ramping up its speed in development of fragment-based drug discovery techniques by employing outsourcing facilities from Asia Pacific. The demand for fragment-based drug discovery in Asia Pacific, on the other hand, is a lot higher than any other major region, owing to the rapid improvements in healthcare infrastructure and focus on better quality management in countries such as Japan and China.

Biopharmaceutical Companies Top the List of Fragment-based Drug Discovery Demand

Fragment-based drug discovery techniques have grown significantly in popularity in the recent years and have found a great scope of use in the biopharmaceuticals. This includes large companies, academic bodies, and CROs. These techniques have helped massively in creating chemical series that possess lead-like properties as they have improved the success rate of creation significantly over the conventional screening methods. Fragment-based drug discovery techniques have also been extremely useful in marking out chemical motifs from multiple targets.

It is a combination of all these factors that are expected to drive the use of fragment-based drug discovery in biopharmaceutical facilities to a revenue generation of US$565.2 mn by the end of 2023. The key providers of fragment-based drug discovery programs include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Sygnature Discovery, Evotec A.G., and Beactica AB.

Fragment-based Drug Discovery Market is Anticipated to Reach a Value of US$ 1.15 Bn by 2023

The increasing search for new drugs to treat complicated medical problems has led to a surge in the global fragment-based drug discovery market. Furthermore, the growth of the global fragment-based drug discovery market has also led to dominance of biopharmaceutical companies, as the market requires a system for identification of lead compounds in the process of drug discovery.

The report published by Transparency Market Research on the global fragment-based drug discovery market gives a comprehensive overview of the important dynamics and trends. The report assesses the threat from new entrants, threat of substitute products or services, bargaining power of customers, bargaining power of suppliers, and the intensity of competitive rivalry with the help of a Porter’s five forces analysis. Furthermore, it also evaluates the strengths, weaknesses, opportunities, and threats of the market with the help of a SWOT analysis. The report gives a clear understanding of the competitive landscape and segmentation of the market and an overview of the global fragment-based drug discovery market to enable its readers to make well-informed business decisions.

Report Overview @ https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

Overview of Global Fragment-Based Drug Discovery Market

The drivers for the global fragment-based drug discovery market are its time-saving attributes and quick access to biophysical fragment screening techniques. Fragment-based drug discovery has become a method of designing unique molecules. This technique uses smaller ‘fragments or ligands’, which have lower molecular weights. The main restraint on the global fragment-based drug discovery market is the weak potency of a few compounds that are derived from fragment screening. The other conspicuous restraint on this market is the need for special ‘fragment libraries’ for conducting research.

The global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. The fragment screening segment is further sub-segmented into biophysical techniques and non-biophysical techniques. Biophysical techniques include isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy, fluorescence polarization (FP), differential scanning fluorimetry (DSF), surface plasmon resonance, X-ray crystallography, assay (thermal shift), biolayer interferometry, capillary electrophoresis, mass spectrometry, and others (biochemical assays). The end-use applications encouraging the growth of this market are CROs, biopharmaceutical companies, and academic and research institutions. Geographically, the global fragment-based drug discovery market is divided into regions such as North America, Asia Pacific, Europe, Latin America, and Rest of the World.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

North America dominated the global fragment-based drug discovery market due to growing awareness about this sector and the high level of its adoption by pharmaceutical companies. However, in the coming years, the Asia Pacific fragment-based drug discovery market will witness phenomenal growth due to the growing number of research and development activities.

Companies Mentioned in the Global Fragment-Based Drug Discovery Market Report

The important players in the global fragment-based drug discovery market are Astex Pharmaceuticals, Beactica AB, Structure Based Design, Inc., Alveus Pharmaceuticals Pvt. Ltd., Emerald BioStructures, Inc., Evotec AG, Crown Bioscience, Inc., Kinetic Discovery Limited, Sprint Bioscience, Proteros Fragments GmbH, Charles River Laboratories International, Inc., and Sygnature Discovery.

Fragment-based Drug Discovery Market is Anticipated to Reach a Value of US$ 435.6 Mn by 2023

A recent report on the global fragment based drug discovery market studied by Transparency Market Research (TMR) elaborates the factors that indicates the growth of the market in coming years. The market for fragmented based drugs discovery is expected to grow steadily during the forecast period of 2015 to 2023. The increasing popularity of newer techniques in fragment based drug discovery has grown significantly over the past few years. Its increasing scope in the biopharmaceuticals has also grown vastly that will further help the market to grow. Developing techniques has also improved by producing chemical series that contains lead like properties and has helped in creating improved conventional screening methods. The market also includes academic bodies, large companies, and CROs. The key contributors of the fragment based drug discovery market are Sygnature Discovery, Astex Pharmaceuticals, Beactica AB, Evotec A.G., and Charles River Laboratories International Inc

According to TMR, the market for fragment based drug discovery is expected to attain a CAGR of 14.4% during 2015 to 2023. The revenue during the same period is projected to raise up to US$1.15 bn by the end for forecast period of 2023. . The fragment based drug discovery is segmented on the basis of end-user, service component, and geography. The end-user segment includes CROs, academic and research institutions, and biopharmaceuticals companies, among which the contribution of biopharmaceutical companies has grown significantly. Geographically, North America has its dominance for fragmented based drug market. The evaluation for North America is expected to grow up to 45.4% of the entire market during the forecast period.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

The Use of Lower Molecular Weight Has Grown the Demand for Fragment Based Drug Discovery Market

The market is experiencing high demand for fragment based drugs basically to overcome the difficulty faced in various complicated medical conditions. The market for fragment based drug discovery is expanding as it time saving and feasibility to access to fragment screening through biophysical techniques. The significant use of fragment based drug discovery has developed methods to use to design unique molecules, which uses lower molecular weight known as fragments or ligands. The effect of lead discovery has created a large number of fragment-derived compounds, which are significantly used in clinical trials and to treat patients through medicines.

Lesser Number of Fragment Libraries May Restrict the Fragment Based Drug Discovery Market to Grow Further In Future

The fragment based drug discovery market is comprised of five main components such as target enablement, fragment to lead optimization, fragment screening, fragment libraries, and model based on fragment binding. The market has also shown huge interest for covalent fragments, these are the fragments that is made through reaction which forma covalent bond with the protein. On the other hand, the market gets restricted when certain compounds have weak potency derived through fragment screening. Additionally, other restraints faced in the fragment based drug discovery market are lesser number of fragment libraries that will be immensely helpful for conducting further research. Despite certain restraints, fragment based methods has the ability to deliver new results in chemical biology (the use of chemical tools is done to understand and modulate biological systems and functions). Furthermore, the use of fragment based drug discovery is growing which also considers validation and target discovery.